Soft Tissue Sarcoma
Conditions
Brief summary
The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy. Approximately 30 people will take part in this study conducted by investigators at the University of Iowa.
Detailed description
This is a single-arm open-label phase Ib and phase II clinical study assessing the safety and relative efficacy of concurrent talimogene laherparepvec in combination with radiotherapy in patients with soft tissue sarcomas. Patients will be treated with neoadjuvant radiation and weekly intratumoral injections of talimogene laherparepvec. Weekly injections of talimogene laherparepvec will be continued until surgery. Surgery will be performed 4-6 weeks from the end of radiation therapy to allow for resolution of acute toxicities per current standard of care.
Interventions
DRUGTalimogene Laherparepvec
Talimogene Laherparepvec
RADIATIONRadiotherapy
Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Sponsors
Amgen
University of Iowa
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject has provided informed consent. * Histologically confirmed diagnosis of locally advanced STS that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate. EXAMPLES: * Resectable stage IIB, III, and IV disease that are not suitable for surgically resection alone due to inability to achieve clear margins. * Including metastatic (stage IV) disease for which radiotherapy and surgical resection are indicated. * Except certain histologic subtypes: GIST, Desmoid, Ewing sarcoma, Kaposi sarcoma, and bone sarcomas. * Previous treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least 1 year prior to enrollment. * No prior Talimogene laherparepvec or tumor vaccines allowed. * No prior radiation to the same tumor bed allowed. * Age ≥18 years. * Both men and women of all races and ethnic groups are eligible for this trial. * ECOG performance status ≤1. * Patient must have measurable disease: * Tumor size at least ≥ 5 cm in the longest diameter as measured by CT scan or MRI for which radiation is feasible. * Patient must have injectable disease (direct injection or ultrasound guided).
Exclusion criteria
* Certain histologic subtypes: GIST, Desmoid, Ewing sarcoma, Kaposi sarcoma, and bone sarcomas. * History or evidence of sarcoma associated with immunodeficiency states (e.g.: Hereditary immune deficiency, HIV, organ transplant or leukemia). * Subjects with retroperitoneal and visceral sarcoma. * History or evidence of gastrointestinal inflammatory bowel disease (ulcerative colitis or Crohn's disease) or other symptomatic autoimmune disease including, inflammatory bowel disease, or history of any poorly controlled or severe systemic autoimmune disease (i.e., rheumatoid arthritis, systemic lupus erythematosus, scleroderma, type I diabetes, or autoimmune vasculitis). * History of other malignancy within the past 3 years except treated with curative intent and no known active disease present and has not received chemotherapy for ≥ 1 year before enrollment/randomization and low risk for recurrence. * History of prior or current autoimmune disease. * History of prior or current splenectomy or splenic irradiation. * Active herpetic skin lesions * Require intermittent or chronic treatment with an anti-herpetic drug (e.g., acyclovir), other than intermittent topical use. * Any non-oncology vaccine therapies used for the prevention of infectious disease within 28 days prior to enrollment and during treatment period. * Concomitant treatment with therapeutic anticoagulants such as warfarin. * Known human immunodeficiency virus (HIV) disease (requires negative test for clinically suspected HIV infection). * Acute or chronic hepatitis B or hepatitis C infection (requires negative test for clinically suspected hepatitis B or hepatitis C infection). * Evidence of hepatitis B - 1. Positive HBV surface antigen (indicative for chronic hepatitis B or recent acute hepatitis B). 2. Negative HBV surface antigen but positive HBV total core antibody (indicative for resolved hepatitis B infection or occult hepatitis B) and detectable copies of HBV DNA by PCR (detectable HBV DNA copies suggest occult hepatitis B). * Evidence of hepatitis C - 1\. Positive HCV antibody and positive HCV RNA by PCR (undetectable RNA copies suggest past and resolved hepatitis C infection). * Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment and through 3 months after the last dose of study treatment. * Female subjects of childbearing potential or male subjects who are unwilling to use 2 highly effective methods of contraception during study treatment and through 3 months after the last dose of study treatment. See Section 7.5 for more details. * Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s). * Other investigational procedures while participating in this study that could affect the primary objective of the study as determined by the PI are excluded. * Subject previously has entered this study. * Patients who are receiving any other investigational agents. * Evidence of CNS metastases. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to talimogene laherparepvec. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Patients on or requiring immunosuppressive therapies. * Any of the following laboratory abnormalities: * Hemoglobin \< 9.0 g/dL * Absolute neutrophil count (ANC) \< 1500 per mm3 * Platelet count \< 100,000 per mm3 * Total bilirubin \> 1.5 × ULN * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 × ULN * Alkaline phosphatase \> 2.5 × ULN * PT (or INR) and PTT (or aPTT) \> 1.5 × ULN * Creatinine \> 2.0 × ULN
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs) | 14 weeks | A DLT is defined as any of the following talimogene laherparepvec-related toxicity or related to the combination of talimogene laherparepvec and radiation therapy during treatment and up to 4 weeks after the last talimogene laherparepvec injection: Grade 3 or greater immune-mediated adverse events, Grade 3 or greater allergic reactions, any grade plasmacytoma, any other unexpected grade 3 or greater hematologic or non-hematologic toxicity, with the exceptions of: any grade of alopecia, expected radiation related skin toxicity of any grade, Grade 3 arthralgia or myalgia, brief (\< 1 week) grade 3 fatigue, Grade 3 fever, Grade 3 diarrhea or vomiting responding to supportive case. |
| Phase 2: Pathologic Tumor Necrosis Rate | 14 weeks | Pathologic tumor necrosis rate is defined as the percentage of subjects with pathologic tumor necrosis ≥ 95%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | 24 months | Overall response rate is defined as the percentage of patients with a confirmed complete or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT: Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is a 30% decrease in the sum of the longest dimensions of the target lesions, relative to baseline. Progressive disease (PD) is an increase of 20% or more in the sum of the longest dimension of target lesions. Stable disease (SD) is a decrease in the tumor size of \< 30% or an increase of \< 20%. |
| Percentage of Participants With 2 Year Progression-Free Survival | 24 months | Progression-free survival is defined as the time from treatment initiation to the date of first documentation of disease progression or death due to any cause. Otherwise, patients are censored at the date of last radiographic assessment for progression. |
| Percentage of Participants With 2 Year Overall Survival | 24 months | Overall survival is defined as the time from treatment initiation to death due to any cause. Patients still alive are censored at last date known to be alive. |
| Number of Participants With Adverse Events (AEs) | 14 weeks | To further assess the safety of talimogene laherparepvec given concurrently with preoperative external beam radiation in sarcoma patients.Information regarding the occurrence of adverse events will be collected from the time the subject signs the informed consent form and throughout their participation in the study, including a period of 30 days after the last dose of study drug. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment talimogene laherparepvec in combination with radiotherapy
talimogene laherparepvec: talimogene laherparepvec
Radiotherapy: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines. | 30 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Treatment |
|---|---|
| Age, Continuous | 61 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 29 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 29 Participants |
| Region of Enrollment United States | 30 participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 21 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 30 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 4 / 30 |
Outcome results
Primary
Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs)
A DLT is defined as any of the following talimogene laherparepvec-related toxicity or related to the combination of talimogene laherparepvec and radiation therapy during treatment and up to 4 weeks after the last talimogene laherparepvec injection: Grade 3 or greater immune-mediated adverse events, Grade 3 or greater allergic reactions, any grade plasmacytoma, any other unexpected grade 3 or greater hematologic or non-hematologic toxicity, with the exceptions of: any grade of alopecia, expected radiation related skin toxicity of any grade, Grade 3 arthralgia or myalgia, brief (\< 1 week) grade 3 fatigue, Grade 3 fever, Grade 3 diarrhea or vomiting responding to supportive case.
Time frame: 14 weeks
Population: 6 participants were evaluable for DLT assessment
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment | Phase 1b: Number of Subjects With Dose Limiting Toxicities (DLTs) | 0 Participants |
Primary
Phase 2: Pathologic Tumor Necrosis Rate
Pathologic tumor necrosis rate is defined as the percentage of subjects with pathologic tumor necrosis ≥ 95%.
Time frame: 14 weeks
Population: In Phase 2, 24 subjects were accrued. One patient refused surgery resulting in 23 subjects being evaluated.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment | Phase 2: Pathologic Tumor Necrosis Rate | ≥ 95% | 5 Participants |
| Treatment | Phase 2: Pathologic Tumor Necrosis Rate | < 95% | 18 Participants |
Secondary
Number of Participants With Adverse Events (AEs)
To further assess the safety of talimogene laherparepvec given concurrently with preoperative external beam radiation in sarcoma patients.Information regarding the occurrence of adverse events will be collected from the time the subject signs the informed consent form and throughout their participation in the study, including a period of 30 days after the last dose of study drug.
Time frame: 14 weeks
Population: All 30 enrolled subjects were assessed for AEs
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment | Number of Participants With Adverse Events (AEs) | 30 Participants |
Secondary
Overall Response Rate
Overall response rate is defined as the percentage of patients with a confirmed complete or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT: Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is a 30% decrease in the sum of the longest dimensions of the target lesions, relative to baseline. Progressive disease (PD) is an increase of 20% or more in the sum of the longest dimension of target lesions. Stable disease (SD) is a decrease in the tumor size of \< 30% or an increase of \< 20%.
Time frame: 24 months
Population: Subjects completing Phase 1 and 2.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment | Overall Response Rate | Complete Response | 0 Participants |
| Treatment | Overall Response Rate | Partial Response | 1 Participants |
| Treatment | Overall Response Rate | Stable Disease | 20 Participants |
| Treatment | Overall Response Rate | Progressive Disease | 9 Participants |
Secondary
Percentage of Participants With 2 Year Overall Survival
Overall survival is defined as the time from treatment initiation to death due to any cause. Patients still alive are censored at last date known to be alive.
Time frame: 24 months
Population: Subjects in Phase 1 and 2.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment | Percentage of Participants With 2 Year Overall Survival | 77 percentage of participants |
Secondary
Percentage of Participants With 2 Year Progression-Free Survival
Progression-free survival is defined as the time from treatment initiation to the date of first documentation of disease progression or death due to any cause. Otherwise, patients are censored at the date of last radiographic assessment for progression.
Time frame: 24 months
Population: Subjects completing Phase 1 and 2.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment | Percentage of Participants With 2 Year Progression-Free Survival | 57 percentage of participants |